Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies

摘要: The receptor for advanced glycation end products (RAGE), a member of immunoglobulin superfamily, has been proved to stimulate survival, growth, and metastatic spread cancers cells. Evidence suggested that the 82G/S, −374T/A, −429T/C polymorphisms in RAGE promoter region might affect risk cancer; however, data from epidemiological studies showed conflicting results remain be further clarified. This meta-analysis was performed derive more precise estimation cancer. A comprehensive electronic search conducted articles published up until December 2, 2014, Medline (PubMed), Embase, Cochrane Library Google Scholar. total 12 case–control were included this meta-analysis, providing 3,374 cases 3,757 controls 2,936 3,338 2,882 3,279 specifically. pooled odds ratio (OR) with 95 % confidence interval (CI) calculated evaluate associations Overall, we observed significantly increased cancer relation 82G/S (A vs. G: OR 1.321, CI 1.164–1.499, Phet 0.028; AA GG: 1.823, 1.541–2.157, < 0.001; AG 1.399, 1.120–1.746, 0.002; GA+AA 1.470, 1.187–1.821, GG+AG: 1.416, 1.158–1.732, 0.107) reduced −374T/A (AA TT: 0.818, 0.686–0.976, 0.025; T: 0.908, 0.840–0.981, 0.014). In subgroup analysis elevated indicated population Asian patients lung cancer, Caucasian breast But no significant association between Thus, revealed polymorphism is associated while cancers.